We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.60 | 1.00 | 100.00 | 0.00 | 12:16:40 |
From May 2019 to May 2024
By Chris Wack
BioNTech SE said in a filing Tuesday it is planning on selling American Depositary Shares in its initial public offering for an expected $18 to $20 an ADS.
The Germany-based oncology treatment company said it would sell 13.2 million ADSs, while granting the underwriters the option of buying 1.98 million ADSs. BioNTech said to date it has raised $1.3 billion of capital in private placements and from its collaborators, which include Genentech, Sanofi, Genmab, Genevant Sciences, Eli Lilly, Bayer AG and Pfizer.
For the first six months of 2019, BioNTech said it had revenue from contracts with customers of 51.9 million euros, compared to EUR43.4 million in the same period a year earlier. The company reported a loss for the first half of 2019 of EUR90.7 million, compared to 2018's loss of EUR23.3 million.
BioNTech said it plans on listing its ADSs on the Nasdaq under the symbol BNTX.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 24, 2019 06:55 ET (10:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
